Kimberly-Clark, the Texas-based maker of Kleenex and Huggies, has agreed to sell its personal protective equipment business to Australia's Ansellfor $640 million in cash.
Why it matters: It wasn't too long ago that America was wringing its ungloved hands over how much PPE manufacturing had moved overseas.
A new Mayo Clinic study finds rural COVID-19 patients were 22% likelier to die after a hospital stay than their urban counterparts and that disparities persisted despite the rollout of coronavirus vaccines.
Why it matters: The findings underscore how the U.S. rural population is one of the most medically vulnerable groups, often having limited access to high-quality post-acute, primary, and specialty care, researchers wrote.
Former President Trump is refusing to back a national abortion ban, but he could still sharply restrict the procedure if he returns to the White House.
Why it matters: Trump's long-promised statement on abortion Monday didn't clear up whether he would wield executive power to force through limits that anti-abortion advocates are agitating for.
The big picture: Thepresumptive GOP presidential nominee said Monday that abortion laws should be left to the states to decide, though he did not take a stance on whether he supports a national limit.
Former President Donald Trump on Monday formally announced his position on abortion rights, saying the issue should be left up to states to decide.
Why it matters: The announcement contrasts Trump's earlier hints that he would support a national abortion ban and risks angering anti-abortion rights groups who favor restrictions on the national level.
Why it matters: NASA warns "it is not safe to look directly at the Sun without specialized eye protection for solar viewing" except during the brief total phase of a total solar eclipse.
Federal advisers on nuclear medicine safety had conflicts of interest when they evaluated whether accidental injections of radioactive drugs used in medical imaging should be reported to authorities, according to a watchdog report.
Why it matters: The special inquiry found the Nuclear Regulatory Commission doesn't have a policy requiring conflict-of-interest reviews and therefore lacks controls to ensure compliance with federal ethics guidelines.
Less than half of the cancer drugs recently receiving accelerated approval from the Food and Drug Administration ultimately showed clinical benefit in trials after five years, a new JAMA study finds.
Why it matters: There's been growing scrutiny around the FDA's fast-track process for allowing drugmakers to launch products on preliminary evidence and charge high prices before completing trials.
